Lilly France

Lilly Asia Ventures, established in 2008 and based in Shanghai, China, serves as the corporate venture capital arm of Eli Lilly and Company. The firm focuses on making investments in the life sciences and healthcare sectors, primarily targeting opportunities in China but also considering ventures in other parts of East and South Asia. Lilly Asia Ventures seeks to invest in companies at various stages, from seed to later stages, with a preference for those showcasing strong management teams and innovative technologies or business models. The investment strategy emphasizes human therapeutics, medical technology, healthcare services, and broader life sciences. Typically, investments range from $5 million to $15 million per round, with an inclination towards acquiring minority stakes, usually under 20 percent. The firm aims to play an active role in its portfolio companies by seeking board seats or observation rights.